GlassScriptPhysician profile
Suzanne Tompkins
NPI 1871965236
$5,385.64
in general payments reported to CMS, 2019-2025
40 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,191 · 2022: $1,176 · 2023: $1,519 · 2024: $884 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $768.01 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $645.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $464.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $389.72 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $328.42 | 2021-2024 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $317.03 | 2021-2024 | Trelegy Ellipta |
| Abbvie INC. | $303.14 | 2022-2025 | |
| Corium, LLC | $280.60 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $205.54 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $203.47 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $181.74 | 2021-2023 | Steglatro, Belsomra, Steglujan |
| Takeda Pharmaceuticals U.S.A., INC. | $175.44 | 2021-2022 | |
| Pfizer INC. | $146.19 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $119.47 | 2023-2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.96 | 2022-2024 | Xifaxan, Trulance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.